Tyrosine
CAS 60-18-4
Tyrosine (CAS 60-18-4) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 8 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 27685.691176470587 nM | 34 | - |
| - | IC50 | 47000 nM | 3 | - |
| - | Potency | 4775.5 nM | 1 | - |
| Large neutral amino acids transporter small subunit 1 Transporter |
IC50 | 4.17 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Foetal growth restriction | 15 | 50.849 | 10070531 |
| Device related sepsis | 10 | 37.139 | 10069802 |
| Infantile apnoea | 8 | 36.902 | 10077321 |
| Selective eating disorder | 8 | 32.256 | 10078069 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Tyrosine | 10962 | SU | MTHSPL |
| TYROSINE | 10962 | SU | MTHSPL |
| tyrosine | 10962 | IN | RXNORM |
| L-tyrosine | 10962 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Tyrosine used for in pharmaceutical contexts?
Tyrosine (CAS 60-18-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Tyrosine?
Tyrosine has 8 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Device related sepsis, Infantile apnoea, Selective eating disorder, Attention deficit hyperactivity disorder. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Tyrosine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for L-Tyrosine with EU status "permitted".
What clinical phase is Tyrosine in?
Tyrosine is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Tyrosine?
Tyrosine has 4 bioactivity rows in this page query. Rendered target entries include Large neutral amino acids transporter small subunit 1.